Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg IN PATIENTS WITH DYSFUNCTIONAL UTERINE BLEEDING REQUIRING ENDOMETRIAL ABLATION.

NCT04428684 is registered in ClinicalTrials.gov with Peptigroupe Inc. as lead sponsor.

NCT NCT04428684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04428684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg IN PATIENTS WITH DYSFUNCTIONAL UTERINE BLEEDING REQUIRING ENDOMETRIAL ABLATION.
Lead sponsor
Peptigroupe Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 29, 2018
Completion date
June 7, 2020
Enrollment
80 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

dysfunctional uterine bleeding